Skip to content 
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 52.42M | 87.29M | [{"date":"2024-12-31","value":60.05,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (52.42M) | (87.29M) | [{"date":"2024-12-31","value":-5241600000,"profit":false},{"date":"2025-12-31","value":-8729400000,"profit":false}] | |||
| Total Non-Operating Income/Expense | - | 13.19M | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Pre-Tax Income | (46.88M) | (74.11M) | [{"date":"2024-12-31","value":-4687900000,"profit":false},{"date":"2025-12-31","value":-7410800000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (46.88M) | (74.88M) | [{"date":"2024-12-31","value":-4687900000,"profit":false},{"date":"2025-12-31","value":-7488100000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (46.88M) | (74.88M) | [{"date":"2024-12-31","value":-4687900000,"profit":false},{"date":"2025-12-31","value":-7488100000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| SPTX | |
|---|---|
| ROA (LTM) | -18.90% |
| ROE (LTM) | -28.08% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| SPTX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Seaport Therapeutics, Inc. Common Stock (SPTX) share price today is $16.44
Yes, Indians can buy shares of Seaport Therapeutics, Inc. Common Stock (SPTX) on Vested. To buy
Yes, you can purchase fractional shares of Seaport Therapeutics, Inc. Common Stock (SPTX) via the Vested app. You can start investing in Seaport Therapeutics, Inc. Common Stock (SPTX) with a minimum investment of $1.
You can invest in shares of Seaport Therapeutics, Inc. Common Stock (SPTX) via Vested in three simple steps:
The 52-week high price of Seaport Therapeutics, Inc. Common Stock (SPTX) is $23. The 52-week low price of Seaport Therapeutics, Inc. Common Stock (SPTX) is $0.01.
The price-to-earnings (P/E) ratio of Seaport Therapeutics, Inc. Common Stock (SPTX) is
The price-to-book (P/B) ratio of Seaport Therapeutics, Inc. Common Stock (SPTX) is 0.00
The dividend yield of Seaport Therapeutics, Inc. Common Stock (SPTX) is 0.00%
The market capitalization of Seaport Therapeutics, Inc. Common Stock (SPTX) is $948.14M
The stock symbol (or ticker) of Seaport Therapeutics, Inc. Common Stock is SPTX
Consider the share price of Seaport Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Seaport Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Seaport Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Seaport Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Seaport Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Seaport Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
